BAM15 has encouraging metabolic results in animal studies, but it has not been established as a human treatment. Human dose, benefit and safety remain unknown.
Still uncertain: Human benefit, dose, safe exposure range, long-term safety or suitability as an oral lifestyle compound.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
Obesity, insulin resistance and metabolic research
Human evidence
No therapeutic human trial evidence was identified.
Regulatory status
No FDA/EMA-approved medicine identified.
Main limitations
Human efficacy, dose, therapeutic window, chronic safety or suitability as an oral lifestyle compound.
Safety
Mitochondrial uncoupling is intrinsically safety-sensitive; human therapeutic window, cardiac/thermal risks and chronic toxicity are unknown.
Evidence reviewed
2026-09-18
i
No therapeutic human trial evidence was identified.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.
Evidence synthesis
✓Compelling animal signal exists, but no human efficacy or safe therapeutic window has been established.
Important limitations
!Mitochondrial uncoupling can become dangerous if excessive; preclinical selectivity does not eliminate class risk.
Selected study & evidence records
Discovery of BAM15 mitochondrial uncoupler
2014 · Preclinical mechanistic/animal study
BAM15 uncoupled mitochondrial respiration without the same plasma-membrane depolarization seen with some comparator uncouplers and showed mouse bioactivity.
Mitochondrial uncoupling is intrinsically safety-sensitive; human therapeutic window, cardiac/thermal risks and chronic toxicity are unknown.
Mitochondrial uncoupling is intrinsically safety-sensitive; human therapeutic window, thermal/cardiac risk and chronic toxicity are unknown despite preclinical selectivity claims.
Technical details
Mechanism / biologyMitochondrial protonophore that increases energy expenditure by partially uncoupling oxidative phosphorylation in experimental models.
Route / formulation boundaryThis is not a peptide; commercial oral products have no established clinical validation.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No human systemic administration regimen identified; human-derived-cell and preclinical work do not establish a human dose or safety window.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
1outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
